He Bi Shi

Acute ischemic stroke is a leading cause of death worldwide, and intravenous thrombolysis with recombinant tissue plasminogen activator rt-PA within 4.5 hours of symptom onset is the most effective treatment currently available. However, some patients experience stroke progression and early reocclusion after thrombolysis, which can worsen neurological outcomes. This trial evaluates whether early antiplatelet therapy with oral aspirin, given soon after thrombolysis, can improve recovery without increasing bleeding risks. The study randomly assigns patients to receive either early oral aspirin within 3 hours of starting intravenous thrombolysis or a placebo, alongside the best medical care based on current guidelines. Aspirin is administered as a 300 mg dose, either chewed or given via nasogastric tube if swallowing is difficult. The trial includes a control group receiving placebo under similar conditions to compare outcomes. This is a Phase 3, multicenter, quadruple-blind, randomized clinical trial. During the study, participants will be closely monitored for neurological status and functional recovery using the modified Rankin scale at 30 and 90 days after stroke, as well as other assessments like NIH Stroke Scale scores within the first week. Researchers will track early neurological changes and safety outcomes such as intracranial hemorrhage. Follow-up will include evaluations at multiple time points up to 90 days post-stroke to determine the effects of early antiplatelet treatment on stroke recovery.

Researchers are evaluating treatment options for patients infected with Helicobacter pylori HP, a common stomach infection. This prospective, multicenter study enrolls 200 patients who test positive for HP through rapid urease tests or 13C urea breath tests. The study aims to assess the success rate of HP eradication, side effects, patient compliance, antibiotic resistance, and how these factors impact treatment outcomes. Participants will receive one of two experimental treatments a high-dose dual therapy consisting of Vonoprazan, a potassium competitive acid blocker, and Amoxicillin, an antibiotic or a minocycline-containing quadruple therapy including Bismuth Potassium Citrate for stomach protection, along with Minocycline and Metronidazole antibiotics. Patients will undergo HP culture and drug sensitivity tests before treatment. The study is non-randomized and does not use blinding. Throughout the study, patients will be monitored for HP eradication six weeks after finishing therapy. Researchers will also track adverse effects and treatment compliance within seven days following therapy completion. Participation involves informed consent and ongoing assessments to evaluate treatment effectiveness and safety. The total participation period extends at least six weeks after therapy to assess outcomes and side effects.

Chronic obstructive pulmonary disease COPD is a common long-term respiratory condition often accompanied by other health problems. This research aims to gather real-world data on managing COPD alongside these additional conditions using a combination of Chinese and Western medicine approaches. The study focuses on understanding risk factors for high-risk groups and patients with confirmed comorbidities, developing models to predict risks of comorbidities and acute COPD flare-ups, and improving long-term care strategies with early detection across hospitals, communities, and homes. Participants will receive routine clinical care following current guidelines, with no study-mandated treatments assigned. Data will be collected through standard clinical evaluations such as symptom questionnaires, lung function tests, imaging, and biomarker analysis. Additionally, continuous multisensor digital monitoring will track heart rate, blood pressure, activity, sleep, and other physiological and behavioral signs. Traditional Chinese Medicine assessments including tongue, pulse, and facial diagnostics will also be performed to provide comprehensive digital phenotyping. Throughout the study, participants will be regularly assessed by clinical tests, questionnaires, and continuous monitoring devices. Researchers will measure the annual rate of COPD exacerbations and the occurrence of related comorbidities such as hypertension, heart disease, arrhythmia, heart failure, and diabetes over up to 36 months. This extensive monitoring aims to support evidence-based management and early warning systems for COPD with comorbidities. The total study duration and follow-up will be up to three years.

Researchers are evaluating the safety and effectiveness of low-dose tenecteplase in elderly patients aged 70 and older who have experienced an acute ischemic stroke. This multicenter, randomized controlled trial focuses on treatment within 4.5 hours of stroke onset to assess how this therapy may improve neurological outcomes compared to a standard dose. Participants are randomly assigned to receive either a low dose 0.175 mgkg, up to 17.5 mg or a standard dose 0.25 mgkg, up to 25 mg of tenecteplase given intravenously. The study is designed as a parallel-group trial comparing these two dosing regimens to understand which may be more beneficial and safe for elderly stroke patients. Participants will be monitored for recovery and safety through neurological assessments using scales such as the Modified Rankin Scale and the National Institutes of Health Stroke Scale up to 90 days after treatment. Outcomes like neurological improvement, functional independence, quality of life, and any bleeding events will be closely measured. The trial will continue until December 2028, with follow-up visits planned to evaluate participants progress and overall health.

Researchers are conducting a multicenter, prospective observational study across 200 hospitals in China to examine current treatment patterns for chronic hepatitis B CHB. The study aims to compare patient outcomes under different treatment regimens to provide evidence-based data that can improve CHB treatment strategies and follow-up care, ultimately advancing efforts toward a functional cure for chronic hepatitis B. Participants include those receiving or planned to receive treatments such as entecavir ETV, tenofovir disoproxil fumarate TDF, tenofovir alafenamide fumarate TAF, tenofovir amibufenamide TMF, or peginterferon alpha-2b injection. The study observes real-world clinical practice without assigning treatments, capturing data on these therapies over an extended period. During the study, researchers will monitor outcomes including the percentage of patients developing HBsAg-associated hepatocellular carcinoma HCC, incidence of HCC, rates of HBsAg seroclearance and seroconversion, changes in HBsAg levels, HBV DNA levels, liver fibrosis improvement, and liver-related complications. Data collection spans from week 4 up to week 240, with continuous follow-up to assess treatment effects and patient status over time.

Researchers are evaluating the safety and effectiveness of Qishen Yiqi Dripping Pills for treating adults aged 18 to 80 with chronic heart failure characterized by reduced ejection fraction due to coronary heart disease, specifically involving Qi deficiency with blood stasis syndrome. This phase 3 trial aims to compare these pills with a placebo to understand their impact on this condition. Participants will receive either Qishen Yiqi Dripping Pills or a matching placebo, both taken orally as 2 bags three times a day, half an hour after meals, over a 12-week period. The study uses a randomized, parallel design with quadruple masking to assess the effects. During the 12 weeks, participants will be monitored through various assessments including the 6-minute walk test, echocardiographic measurements, heart failure symptom evaluations, laboratory tests for biomarkers like NT-proBNP, and quality of life questionnaires. Researchers will track changes from baseline at weeks 4, 8, and 12 to evaluate exercise capacity, symptom improvement, heart function, and safety outcomes throughout the study.

Researchers are studying patients who have had an acute ischemic stroke caused by a blockage in a large blood vessel in the brain. The trial focuses on the safety and effectiveness of remote ischemic conditioning RIC as an additional treatment to improve recovery after endovascular thrombectomy, a procedure that removes the blockage. This research addresses the challenge that even when blood flow is restored, many patients still have poor outcomes or die, possibly due to brain injury during and after the procedure. The study compares three groups one receiving only endovascular thrombectomy and best medical care, a second group receiving thrombectomy plus RIC treatment for 14 days, and a third group receiving thrombectomy plus RIC for 30 days. RIC is a noninvasive device treatment where a cuff on the upper arm inflates and deflates in cycles, applied once before thrombectomy and twice daily afterward. Best medical management follows clinical guidelines for all groups. Participants will be monitored closely for 90 days after stroke. Researchers will assess recovery using the modified Rankin Scale to measure functional independence and will record neurological improvements, brain infarct size, adverse events, and quality of life. The study includes imaging, neurological exams, and safety checks at multiple time points, including 24 hours, 14 days, 72 hours, and 90 days post-treatment to evaluate the impact of RIC on stroke outcomes.